Cargando…
Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study
Background: Pembrolizumab is approved for patients with metastatic urothelial carcinoma (UC) who progressed under platinum therapy. The aim of this study was to assess the efficacy and safety of pembrolizumab in a cohort of real-life UC patients. Methods: This retrospective, observational study incl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870973/ https://www.ncbi.nlm.nih.gov/pubmed/35200579 http://dx.doi.org/10.3390/curroncol29020080 |
_version_ | 1784656884992573440 |
---|---|
author | Dang, Elodie Vallée, Alexandre Lepage-Seydoux, Coralie Sejean, Karine Bonan, Brigitte Abraham, Christine Beuzeboc, Philippe Ratta, Raffaele |
author_facet | Dang, Elodie Vallée, Alexandre Lepage-Seydoux, Coralie Sejean, Karine Bonan, Brigitte Abraham, Christine Beuzeboc, Philippe Ratta, Raffaele |
author_sort | Dang, Elodie |
collection | PubMed |
description | Background: Pembrolizumab is approved for patients with metastatic urothelial carcinoma (UC) who progressed under platinum therapy. The aim of this study was to assess the efficacy and safety of pembrolizumab in a cohort of real-life UC patients. Methods: This retrospective, observational study included advanced UC patients treated with pembrolizumab in a single institution in France. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS) at 6 months. Secondary endpoints were objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and safety. Results: 78 patients were included in the study. The median OS was 7.3 months (3.8–12.2). The estimated OS rate at 6 months was 61.5% (50.5–72.6). The median PFS was 3.1 months (1.4–7.2). The estimated PFS rate at 6 months was 42.3% (31.1–53.5). The best ORR was 35.9%. The mean DOR was 95.5 days. The DCR was 30.8%. The most common treatment-related adverse events (AEs) of any grade were fatigue (46.2%), diarrhea (11.5%), pruritus (10.3%) and nausea (9.0%). There were no grade 3 AEs that occurred with an incidence of 5% or more. Conclusion: Our results confirmed those of randomized clinical trials concerning the treatment with pembrolizumab in patients with advanced UC that progressed after platinum-based chemotherapy. |
format | Online Article Text |
id | pubmed-8870973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88709732022-02-25 Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study Dang, Elodie Vallée, Alexandre Lepage-Seydoux, Coralie Sejean, Karine Bonan, Brigitte Abraham, Christine Beuzeboc, Philippe Ratta, Raffaele Curr Oncol Article Background: Pembrolizumab is approved for patients with metastatic urothelial carcinoma (UC) who progressed under platinum therapy. The aim of this study was to assess the efficacy and safety of pembrolizumab in a cohort of real-life UC patients. Methods: This retrospective, observational study included advanced UC patients treated with pembrolizumab in a single institution in France. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS) at 6 months. Secondary endpoints were objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and safety. Results: 78 patients were included in the study. The median OS was 7.3 months (3.8–12.2). The estimated OS rate at 6 months was 61.5% (50.5–72.6). The median PFS was 3.1 months (1.4–7.2). The estimated PFS rate at 6 months was 42.3% (31.1–53.5). The best ORR was 35.9%. The mean DOR was 95.5 days. The DCR was 30.8%. The most common treatment-related adverse events (AEs) of any grade were fatigue (46.2%), diarrhea (11.5%), pruritus (10.3%) and nausea (9.0%). There were no grade 3 AEs that occurred with an incidence of 5% or more. Conclusion: Our results confirmed those of randomized clinical trials concerning the treatment with pembrolizumab in patients with advanced UC that progressed after platinum-based chemotherapy. MDPI 2022-02-10 /pmc/articles/PMC8870973/ /pubmed/35200579 http://dx.doi.org/10.3390/curroncol29020080 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dang, Elodie Vallée, Alexandre Lepage-Seydoux, Coralie Sejean, Karine Bonan, Brigitte Abraham, Christine Beuzeboc, Philippe Ratta, Raffaele Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study |
title | Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study |
title_full | Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study |
title_fullStr | Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study |
title_full_unstemmed | Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study |
title_short | Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study |
title_sort | clinical benefit of pembrolizumab in advanced urothelial cancer patients in real-life setting: an efficacy and safety monocentric study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870973/ https://www.ncbi.nlm.nih.gov/pubmed/35200579 http://dx.doi.org/10.3390/curroncol29020080 |
work_keys_str_mv | AT dangelodie clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT valleealexandre clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT lepageseydouxcoralie clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT sejeankarine clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT bonanbrigitte clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT abrahamchristine clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT beuzebocphilippe clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy AT rattaraffaele clinicalbenefitofpembrolizumabinadvancedurothelialcancerpatientsinreallifesettinganefficacyandsafetymonocentricstudy |